PDNO

DRUG3 trials

Sponsors

Attgeno AB

Conditions

COVID-19Pulmonary Hypertension

Phase 1

A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension

WithdrawnNCT04885491

Attgeno ABCOVID-19, Pulmonary Hypertension

Start: 2021-05-07End: 2023-04-30Updated: 2023-08-01

A First-in-Human Study to Assess the Safety and Tolerability of PDNO

CompletedNCT04891354

Attgeno ABPulmonary Hypertension

Start: 2021-02-02End: 2022-05-25Updated: 2023-01-19

Phase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery

Attgeno ABPulmonary Hypertension

Start: 2022-10-23End: 2023-12-31Target: 12Updated: 2023-08-01